Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment

J Neural Transm Suppl. 2000:(60):335-43. doi: 10.1007/978-3-7091-6301-6_23.

Abstract

Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are increasingly recognized as alpha-synucleinopathies, i.e. neurodegenerative disorders that share a common subcellular pathology characterized by alpha-synuclein abnormal aggregation. In the present review we focus on depression in alpha-synucleinopathies, discussing epidemiological, pathophysiological and treatment aspects of this frequently disabling clinical feature which may occur in PD, DLB and MSA alike.

Publication types

  • Review

MeSH terms

  • Animals
  • Antidepressive Agents / therapeutic use
  • Brain / physiopathology
  • Depressive Disorder* / drug therapy
  • Depressive Disorder* / epidemiology
  • Depressive Disorder* / physiopathology
  • Diagnosis, Differential
  • Humans
  • Lewy Body Disease / psychology*
  • Multiple System Atrophy / psychology*
  • Nerve Tissue Proteins / metabolism*
  • Parkinson Disease / psychology*
  • Prevalence
  • Synucleins
  • alpha-Synuclein

Substances

  • Antidepressive Agents
  • Nerve Tissue Proteins
  • SNCA protein, human
  • Synucleins
  • alpha-Synuclein